Bristol Myers Squibb and Volastra Therapeutics have entered into a drug discovery collaboration to leverage the latter’s technology platform to discover and develop new oncology drug candidates. The multiyear collaboration, worth up to US$1.1 B, will focus on identifying chromosomal instability-related, synthetic lethal targets as drug candidates for the treatment of metastatic solid tumours. The deal comes only a week after Bristol Myers Squibb announced the approval of its immunotherapy combination of nivolumab and relatlimab as a treatment for melanoma.